International Journal of Tropical Medicine
ISSN: Online 1818-779XISSN: Print 1816-3319
Abstract
Type 2 Diabetes Mellitus (T2DM) is a widespread chronic condition that demands effective management to regulate blood glucose levels and reduce the risk of complications. Imeglimin, an innovative oral anti diabetic drug, has emerged as a promising treatment option. It works through a unique dual mechanism that targets mitochondrial bio energetic, which may enhance glycemic control and offer potential benefits for T2DM management. This randomized, controlled trial evaluated the efficacy and safety of Imeglimin in 120 patients with uncontrolled T2DM, comparing its effects to those of a placebo and metformin. Participants were divided into two groups, with 60 patients receiving Imeglimin and 60 receiving a placebo or continuing their standard metformin treatment. The primary outcomes measured were changes in HbA1c, fasting blood glucose and postprandial glucose levels. Safety assessments were based on the occurrence of adverse events. Imeglimin significantly improved glycemic control compared to the placebo, with 70% of Imeglimin‐treated patients achieving improved control versus 40% in the placebo group (P<0.001). When compared with metformin, Imeglimin led to a greater reduction in HbA1c levels, with 75% efficacy versus 60% in the metformin group (P=0.015). Reductions in fasting and postprandial glucose were also significant (P<0.001). The safety profile of Imeglimin was comparable to that of the placebo, with no significant differences in the rates of adverse or serious adverse events. Imeglimin offers a promising new treatment option for patients with uncontrolled T2DM, demonstrating superior efficacy in glycemic control compared to standard treatments and a favorable safety profile. Further studies are warranted to explore its long‐term benefits and effects in diverse populations.
How to cite this article:
Buddhiraj Patil. Role of lmeglimin in the Management of Uncontrolled Diabetes Mellitus Type 2 for Preventing Complications Like Neuropathy, Nephropathy and Retinopathy.
DOI: https://doi.org/10.36478/10.36478/makijtm.2025.1.66.70
URL: https://www.makhillpublications.co/view-article/1816-3319/10.36478/makijtm.2025.1.66.70